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study was to estimate the cost-effectiveness of ivabradine versus diltiazem as an alter-
native bradycardic agent in these patients. METHODS: A Markov chain Monte Carlo 
simulation model was used to estimate the effect of HR lowering on cardiovascular 
outcomes, including the economic consequences of ivabradine, 7.5 mg twice daily 
versus diltiazem, 240 mg once a day. Included patients had resting HR  70 bpm.  
Outcome events considered were acute myocardial infarction, stroke, heart failure and 
death, as well as revascularization procedures (coronary artery bypass graft and per-
cutaneous coronary interventions). HR distribution was modelled as a gamma func-
tion and survival and time to hospitalization were modelled with weibull functions. 
Health outcomes were measured in life years (LY) and quality-adjusted life years 
(QALY). Time-horizon was set at 20 years and health outcomes and costs were dis-
counted at 1.5% and 4%, respectively. The analysis was conducted following the 
Dutch guidelines for pharmacoeconomic research. RESULTS: For each 100 patients 
assumed to use ivabradine or diltiazem, ivabradine was estimated to gain 44 LY 
(95%CI: [24;70]) and 36 QALY (95%CI: [22;52]) versus diltiazem. Annual incremen-
tal per patient cost of ivabradine versus diltiazem was estimated at a178 (95%CI: 
[138;207]). The incremental cost-effectiveness ratios for ivabradine versus diltiazem 
were estimated at a7990 per LY and a9897 per QALY gained. The probability of   
accepting ivabradine following the informal Dutch willingness-to-pay threshold of 
a20,000 per QALY was estimated at 99%. CONCLUSIONS: Ivabradine was found 
to be a cost-effective alternative for the treatment of SA in patients with resting HR 
 70 bpm with contraindication or intolerance for beta-blockers.    
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OBJECTIVES: The aim of this study was to assess the clinical and economic beneﬁts 
of the stroke units compared with conventional care. METHODS: A Markov model 
was developed. Four clinical conditions were deﬁned : ﬁrst ischaemic event, ﬁrst cere-
bral haemorrhage, recurrent ischaemic , recurrent haemorrhagic. Three lines of man-
agement were identiﬁed after hospitalisation: rehabilitation, home, and geriatric 
institutions. Three levels of incapacity were identiﬁed using the Barthel index. 
The clinical beneﬁt was measured as survival without loss of independence (Barthel 
95–100). The relative risks of death or institutionalisation, or death or dependence 
after passage through a stroke unit were analysed in comparison with conventional 
hospital services from the data available in the Cochrane meta-analyse on stroke 
units. All of the cost calculations were made from the perspective of the health care 
system. Expenditures were discounted at a rate of 5%. RESULTS: The mean cost per 
patient at 5 years was a30,983 in a conventional care unit and a34,638. in a stroke 
unit.After 5 years, the cumulative expenditure for the care of 120,000 patients 
in conventional care units was a3.710 million. Where care is generalised in a stroke 
unit, this ﬁgure increases to a4.160 million. In the 5 years following hospitalisation, 
patients cared for in stroke units survive for more trimesters without sequalae than 
those cared for conventionally (11.6 vs. 8.28). Comparison of the additional cost and 
added efﬁcacy gave a ratio of a1359 per year of life gained without disability (Barthel 
95–100). a513). CONCLUSIONS: The cost-effectiveness ratio between for stroke 
units is much lower than the threshold for cost-effectiveness considered acceptable by 
the international scientiﬁc community (a53,400). This extremely favourable ratio 
could justify organisational changes and the establishment of stroke units in the hos-
pital environment.
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OBJECTIVES: In Russian Federation (RF) just 25% of patients with hypertension 
(HT) reach target blood pressure goals. Moreover, patients with concomitant Type-2 
diabetes have a small chance of successful treatment. Direct Renin Inhibitors (DRI) 
—the newest class of antihypertensive drugs with clinically important nephroprotec-
tive properties. The aim of the study was to assess cost-effectiveness ratio of DRI 
aliskiren in treatment of patients with HT, Type-2 diabetes and nephropathy in Russia. 
METHODS: A lifetime Markov model basing on results of AVOID study was devel-
oped. Incremental cost-effectiveness ratio (ICER) of aliskiren  losartan vs placebo  
losartan was assessed. In the model it is conservatively assumed that no additional 
beneﬁt of aliskiren is extended to periods after 6 months according to 6-months 
AVOID trial. Direct medical costs were calculated basing on tariffs of Federal Obliga-
tory Medical Insurance Fund of the RF. Health outcomes were quality-adjusted life 
years (QALY) and life-years gained (LYG). Clinical and economic outcomes were 
discounted at 3.5%. RESULTS: Cost-effectiveness of aliskiren for 60-years old 
patients in HT, Type-2 diabetes and nephropathy is within the range of 280 thous. 
rubles/LYG (300 thousand rubles/QALY) for early overt nephropathy to 525 thou-
sand rubles/LYG (570 thousand rubles/QALY) for microalbuminuria. Sensitivity 
analysis depending on age of patients between 55–65 years old demonstrates non-sig-
niﬁcant difference (o 5%) of ICER. In accordance with the budjet of the RF in 2009, 
gross domestic product per capita is 360 thous. rubles and ICER is within the range 
of values that are considered acceptable for Russian Health Care system. CONCLU-
SIONS: ICER of aliskiren usage in antihypertensive treatment of patients with HT, 
Type 2 diabetes and nephropathy is comparable with ICER of other cardiovascular 
drugs included into Russian reimbursement. So aliskiren have to be available for 
countrywide health care systems regardless of age of patients.
PCV100
THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN 
CHOLESTEROL (HDL-C), NICOTINIC ACID AND ALL-CAUSE 
MORTALITY
Simons WR1, Edwards DM2
1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Abbott Australasia, 
Botany, NSW, Australia
OBJECTIVES: Translate clinical beneﬁts of raising HDL-C into life years saved (LYS) 
using randomized placebo controlled clinical trial data of NIASPAN as monotherapy 
(NER), or in combination with statin (NER/S), in patients with inadequate HDL-C 
control. METHODS: Two analyses were undertaken: translation of clinical beneﬁts 
into survival beneﬁts using NER, and NER/S, in patients lacking optimal HDL-C 
control. Validated equations (HDL-C Mortality Equations), were used to translate 
HDL-C and LDL-C into reductions in mortality. NER effects are taken from placebo-
controlled trials. Comparative efﬁcacy of NER/S is taken from seven clinical trials 
with NER/S versus a statin only. The treatment arms were categorized by dose and 
the weighted average effects were calculated for change from baseline in HDL-C as 
and LDL-C. RESULTS: Applying the regression parameter estimates from the vali-
dated equation (i.e., 1.02 for LDL-C and 1.51 for HDL-C) to NER trial results, and 
after adjusting for the placebo effect, yields the estimated percent reductions in car-
diovascular events, 23.22%, 34.89% and 36.4% at 1000 mg/day, 1500 mg/day and 
2000 mg per day, respectively. Translating increases in HDL-C by adding NER/S after 
adjusting for the statin alone effect are 0.10 mmol/L, 0.2213 mmol/L and 0.2063 mmol/
L for 1,000 mg, 1,500 mg and 2,000 mg per day, yielding 27.16, 59.75, and 55.7 lives 
saved per 10,000 patients. The Prospective Studies Collaborative report a 0.33 mmol/
L increase in HDL-C is associated with about a third (33%) lower IHD mortality. 
Weighted average increases in HDL-C, with NER/S are 0.318 mmol/L. Applying 
change in HDL-C values using the HDL-C Mortality Equations with bootstrapping, 
the hazard ratios are reduced by 29% [95% CI: 0.34 – 0.23], 30% [95% CI: 
0.35 – 0.24] and 32% [95% CI: 0.38 – 0.26]. CONCLUSIONS: Nicotinic acid 
increases survival in patients with low HDL-C when used as NER or NER/S.
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OBJECTIVES: In patients with acute coronary syndromes (ACS) undergoing percuta-
neous coronary intervention (PCI), the TRITON-TIMI 38 trial demonstrated that 
treatment with prasugrel vs. clopidogrel was associated with signiﬁcantly reduced rates 
of atherothrombotic events, though with increased risk of bleeding. We evaluated the 
long-term cost-effectiveness of a 12-month treatment with prasugrel vs. clopidogrel in 
the trial population, excluding patients with prior transient ischemic attack or stroke, 
from the perspective of the German health care system. METHODS: A Markov model 
was developed based on risk equations for cardiovascular death, myocardial infarction 
(MI) or stroke, bleeding, and rehospitalisation, derived from TRITON-TIMI 38 data 
(N  13,608 patients). Hospital readmissions captured during the trial in all patients 
from 8 countries (N  6705) were assigned to German diagnosis related groups, and 
hospitalisation costs continued to accrue beyond 12 months to all surviving patients. 
Long term survival and quality adjusted survival were estimated for the life-time of each 
patient. RESULTS: At 12 months, a difference in drug costs between prasugrel and 
clopidogrel of 105 (branded clopidogrel) to a416 (generic clopidogrel) per patient 
was partially or totally offset by hospital cost savings (a129 per patient) due princi-
pally to reduced rates of revascularization. In the longer-term, prasugrel was associated 
with higher total costs (a42 to a353 per patient), life expectancy gains of 0.07 years, 
due primarily to the reduced rate of MI, and 0.05 additional QALYs, resulting in 
incremental costs per life year saved and per QALY gained of a606 to a5074 and a799 
to a6689, respectively. Probabilistic sensitivity analysis indicated that prasugrel has a 
q79 to 88% probability of being more cost-effective than clopidogrel at a willingness 
to pay of a30,000 per QALY. CONCLUSIONS: Prasugrel given for up to 1 year in 
ACS-PCI patients is likely to be considered a highly cost-effective treatment strategy.
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OBJECTIVES: Albuminuria has been proven to be associated with renal disease 
progression and cardiovascular (CV) events. Limited evidence exists on the cost- 
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effectiveness of screening the general population for elevated albuminuria. The aim of 
this study was to estimate the cost-effectiveness of various ‘screen-and-treat’ scenarios. 
METHODS: A multi-state Markov model was developed to simulate ‘natural course’ 
albuminuria-based progression to dialysis and occurrence of CV-events. Transition 
probabilities were derived from data of the PREVEND study, an observational, 
general population-based cohort study. In the base-case analysis, cost-effectiveness 
was estimated for screening the general population on microalbuminuria (pre-screen-
ing on ﬁrst morning void urinary albumin concentration q20 mg/L and conﬁrmation 
in two 24-hr urine samples with urinary albumin excretion q30 mg). Cost of screening 
and ACE-inhibitor treatment minus savings on dialysis and CV-events was divided by 
life-years gained (LYG) over a 8-years time-horizon, to render the cost-effectiveness 
ratio for the base-case microalbuminuria screening and alternative scenarios. Costs 
(2008 values) and effects were discounted at 4% and 1.5%, respectively. RESULTS: 
Among 1000 subjects identiﬁed with microalbuminuria, 76 versus 124 CV-events, 16 
versus 27 CV-deaths and 3 versus 5 dialysis cases were found for simulating screening 
and treatment versus no screening, respectively. The per-person cost of screening was 
calculated at a926 (a2,003 versus a1,077) and prevention of CV-deaths was estimated 
to gain 0.0421 per-person discounted life years, resulting in a cost-effectiveness of 
a22,000 per LYG. The probability of accepting screening for microalbuminuria with 
maximum willingness-to-pay thresholds of a20,000, a50,000, and a80,000 per LYG, 
was estimated at 54%, 90% and 95%, respectively. Limiting screening to subjects 
aged 50 or 60 even improved cost-effectiveness. Incremental analyses suggest a most 
optimal cost-effectiveness of screening for microalbuminuria. CONCLUSIONS: Our 
current analyses suggest most favorable cost-effectiveness of screening for microalbu-
minuria if compared with other evaluated alternative albuminuria-based scenarios.
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OBJECTIVES: Extended prophylaxis with a low molecular weight heparin (LMWH)         
such as enoxaparin in high risk surgical patients is consistent with the recommendations 
made by the American College of Chest Physicians 8th Conference on Antithrombotic 
and Thrombolytic Therapy. The objective of this study was to compare the costs and 
effectiveness of extended versus non-extended prophylaxis from the perspective of 
Australian public hospitals. METHODS: A decision-analytic model was constructed 
using local treatment algorithms and populated with clinical trial data. A hypothetical 
cohort of 1000 high-risk general surgery patients received enoxaparin 40 mg daily for 
7 days (non-extended prophylaxis) or enoxaparin 40 mg daily for 28 days (extended 
prophylaxis) in an Australian public hospital. Efﬁcacy data were drawn from the 
ENOXACAN II trial (Bergqvist et al, 2002). The modelled simulation estimated the 
incidence of VTE (symptomatic deep vein thrombosis [DVT] and pulmonary embolism 
[PE]) and adverse events (heparin-induced thrombocytopenia [HIT], post-thrombotic 
syndrome [PTS], prophylaxis and treatment-related bleeding, mortality) within 28 
days and one year of initiating prophylaxis. RESULTS: By extending prophylaxis with    
enoxaparin from 7 days to 28 days in 1000 patients, the model estimated 20 fewer 
symptomatic DVTs, 4 fewer symptomatic PEs, 3 fewer deaths, 10 fewer episodes of 
PTS and 140 fewer hospital days. Extending prophylaxis was associated with cost 
savings of $126,242 from the perspective of an Australian public hospital. CONCLU-
SIONS: Extended prophylaxis with enoxaparin 40 mg represents a cost-effective         
treatment option for high-risk general surgery patients in Australia.
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OBJECTIVES: Deep vein thrombosis (DVT) is associated with a high degree of mor-
bidity and requires rapid diagnosis and effective anticoagulant treatment. An accurate 
diagnosis of DVT requires clinical assessment e.g. calculation of pretest-probability 
score (PTP) and objective testing, because the clinical features are non-speciﬁc           
and commonly used imaging techniques can be inconclusive. The use of D-dimer 
assays improves diagnostic accuracy. The aim of this study was to examine the cost-
effectiveness of three different D-dimer assays in the diagnosis of DVT, alone or in 
combination with PTP. METHODS: We construct two decision-analytic models 
(DAM) involving 96 outpatients with clinically suspected acute DVT. First DAM 
involve 96 outpatients and estimate the number needed to screen to ﬁnd one true 
positive patients (NNSTPP) selected for compression ultrasound (CUS) and costs of 
three strategies: DVT screening with D-dimer Plus assay; DVT screening with D-dimer 
Hemosil assay and DVT screening with Vidas D-dimer Exclusion assay. Second DAM 
involves 79 patients selected from the 96 patients according to PTP scoring and esti-
mate NNSTPP and costs of three strategies as for previous model. The cost of strategies 
was calculated on the basis of the consumed resources for diagnostic tests, laboratory 
time and consumables. RESULTS: The perspective of incremental cost-effectiveness 
analysis is the clinical laboratory setting. A diagnostic strategy employing DVT screen-
ing with Vidas D-dimer Exclusion assay had lowest cost per additionally successfully 
diagnosed patient than the strategy employing DVT screening with D-dimer Hemosil 
assay in the ﬁrst DAM (a1.13 vs. 19.15) and second DAM (a8.7 vs. 20.9). CONCLU-
SIONS: In the clinical laboratory setting is sufﬁcient to determine D-dimer concentra-
tion with Vidas D-dimer Exclusion assay for DVT screening. A diagnostic strategy 
using PTP assessment and Vidas D-dimer Exclusion assay effectively diagnoses DVT, 
but expands costs per additionally successfully diagnosed patient.
PCV105
COST-EFFECTIVENESS OF GENEOTYPE-GUIDED DOSING OF SHORT-
TERM USE OF WARFARIN AMONG DVT/PE PATIENTS
Teschemaker AR1, Lawrence W2
1Howard University, Washington, DC, USA, 2Agency for Healthcare Research and Quality, 
Rockville, MD, USA
OBJECTIVES: To conduct a cost-effectiveness analysis (societal perspective) compar-
ing standard anticoagulation care to genetic testing of cytochrome P450 (CYP2C9) 
and vitamin K epoxide reductase complex subunit 1 (VKORC1) to guide short-term 
warfarin therapy among patients with venous thromboembolism (VTE). METHODS: 
A decision model evaluated use of genotype testing to guide initial dosing during 6-
months of warfarin therapy among VTE patients. The clinical and economic outcomes 
were associated with four alternatives: 1) CYP2C9 and VKORC1 genotype; 2) 
CYP2C9 genotype; 3) VKORC1 genotype; and 4) no testing. All clinical probabilities 
were derived from current scientiﬁc literature. Direct-medical and -nonmedical costs, 
and indirect costs were estimated from published databases and literature. Effective-
ness was measured in quality-adjusted life-years (QALYs) at a discounted rate of 3%. 
All costs were in 2007 U.S. dollars. RESULTS: In the base case analysis, the genotype-
guided dosing strategies demonstrated better health outcomes. Assuming a baseline 
prevalence of CYP2C9 associated warfarin sensitivity of 36% and of VKORC1 
 sensitivity of 63%, the marginal cost-effectiveness of the combination of CYP2C9 
and VKORC1 genotype-guided dosing exceeded $100,000/QALY compared with 
VKORC1 testing alone. However, compared with no testing, the cost-effectiveness of 
testing decreased to $0,000/QALY. At a threshold of $100,000/QALY the probabil-
ity for CYP2C9 and VKORC1 genotype-guided dosing to likely be cost-effective 
was 70%.Overall, the cost-effectiveness analysis demonstrated VKORC1 genotype-
guided dosing to be the optimal strategy (probability  0.64). Sensitivity analysis 
showed that for CYP2C9 and VKORC1 genotype-guided dosing to cost less than 
$100,000/QALY it would have to cost less than $440/test or be restricted to patients 
with high risk of bleed given an INR increase (RR  3.9–5.8). CONCLUSIONS: In 
the general population, VKORC1 is cost-effective. However, restricting the testing to 
patients at high risk of bleed, a combination of both genotype-guided dosing is most 
likely to be cost-effective compared with the standard care.
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OBJECTIVES: To evaluate the short-term cost-effectiveness of achieving multiple 
optimal lipid values (MOLV) for fenoﬁbric acid (FFA) co-administered with low- 
cost generic simvastatin (20 mg and 40 mg) compared to co-administration with 
branded rosuvastatin (10 mg and 20 mg) or atorvastatin (20 mg and 40 mg) in post-
menopausal female, elderly (age q 65 years), metabolic syndrome, and diabetic patient       
subgroups with mixed dyslipidemia. METHODS: A disease outcomes model was used 
to estimate MOLV attainment (achieving any 3 of 4 targets: total-C  200 mg/dL, 
LDL-C  130 mg/dL, HDL-C  40 mg/dL or 50 mg/dL pending subgroup, TG  
150 mg/dL) and associated annual drug costs for patients receiving FFA and a statin. 
Subgroup-speciﬁc baseline lipid values, lipid efﬁcacy, and adherence rates were 
obtained from pooled analyses of three 12-week, double-blind, randomized controlled 
trials of FFA co-administered with a statin. FFA and statin costs were based on 
wholesale acquisition costs net of patient copayments. RESULTS: The predicted pro-
portion of patients achieving MOLV for FFA co-administered with moderate-dose 
simvastatin, rosuvastatin, and atorvastatin ranged from 39%–68%, 56%–90%, and 
50%–80%, respectively, across the four patient subgroups. Corresponding per patient 
drug costs ranged from $859–$886, $1730–$1822, and $1718–1896, respectively, 
and per patient costs to achieve MOLV ranged from $1281–$2266, $1926–$3195, 
and $2299–$3415, respectively. The incremental cost effectiveness ratio (ICER) for 
one additional patient achieving MOLV for FFA co-administered with moderate-dose 
rosuvastatin or atorvastatin versus generic simvastatin was $6,376 and $20,552 in 
post-menopausal female; $3,937 and $7,926 in elderly; $5,272 and $8,869 in meta-
bolic syndrome; and $5,412 and $7,426 in diabetic patient subgroups, respectively. 
For low-dose statin combinations, qualitative results were similar though ICERs 
were higher in the elderly and diabetic patient subgroups. CONCLUSIONS: Co-
administration of FFA with low-cost generic simvastatin results in slightly fewer 
patients achieving MOLV but has the lowest annualized cost per MOLV achieved 
compared to equivalent dose combinations with rosuvastatin or atorvastatin in special 
populations.
